Sapropterin Dihydrochloride

Phenylketonuria

Sohag UniversityUNKNOWNPhase 4 / ApprovedActive

A

82/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 78/ 100
Competitive Position: 89/ 100

Competitive context

17 Active assets in the Phenylketonuria cohort.

Asset / Sponsor	Phase	Rating
Phenylase BioMarin Pharmaceutical	Phase 4	A
Ravpal-Peg BioMarin Pharmaceutical	Phase 2	BB
Repinatrabit Otsuka Pharmaceutical Development & Commercialization, Inc.	Phase 3	BB
Escherichia Coli Strain Synb1618 Synlogic	Phase 2	BB
L-Carnitine Mansoura University	Phase 4	BB

View all 26 →

Same molecule, other indications

Sapropterin Dihydrochloride is also rated in:

schizoaffective disorderDormant

BB

Indicative · Phase 2

64 / 100

hypertensive disorderDormant

B

Indicative · Phase 2

57 / 100

schizophreniaDormant

CCC

Indicative · Phase 2

55 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.